Mycobacterial Disease Drug Development Needs Validated Clinical Outcome Assessment
Executive Summary
Experts at US FDA meeting debate tweaking components of existing measures to focus on symptoms – such as cough, fatigue and dyspnea – that are most bothersome to patients with the nontuberculous form of the disease.
You may also be interested in...
LPAD As An Afterthought? Insmed’s Arikayce Reaches US Market Thanks To Limited Population Pathway
Amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex lung disease is first antimicrobial approved under 21st Century Cures Act pathway; LPAD designation request appears to have occurred after an advisory committee recommended approval for more limited population than requested by Insmed.
Insmed's Amikacin Has US FDA Questioning Microbiological Endpoint Vs. Clinical Benefit
Whether converting positive sputum culture to negative will lead to an improvement in how a person feels, functions or survives is at the heart of agency’s review of Insmed’s amikacin liposome inhalation suspension for accelerated approval in mycobacterial lung disease.
Insmed’s Amikacin Gains US FDA Panel Nod For Refractory Lung Disease
But advisory committee recommends against sponsor's broader indication that would include first-line use in adults with nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex; panel narrowly endorses surrogate endpoint of sputum culture conversion.